It is already the second half of the year, and various projects under the Welfare Acceptance Fund are entering the final sprint stage, and everything that needs to be prepared needs to be prepared.
For example, the smart teacher project developed by Zhao Yi before needs to be reviewed by the Ministry of Education. This is something that must be done as soon as possible because there is a lot of content and it takes a long time.
In addition, hospitals at all levels built by Chinese medical companies in various places also need to enter the final stage of construction, leaving more time for internal decoration and installation and commissioning of medical equipment.
More importantly, a technical report on medical diagnosis of various diseases needs to be submitted to the national medical and health department. In particular, the use of some drugs must obtain their permission.
The ones facing the greatest pressure are Chinese pharmaceutical companies. This company is responsible for the research and development of almost all mid- to high-end medical drugs and medical equipment, especially the research and development of specific drugs for difficult and complicated diseases and imported substitute drugs.
It can be said that the technology is difficult and the research and development tasks are heavy. This is because Zhao Yi provided them with almost all the research and development information on drugs and medical machinery. Otherwise, it would be impossible to achieve success in this task within one year.
Fortunately, those commonly used medical drugs and medical equipment do not require repeated research and development by Chinese pharmaceutical companies. It is better to purchase existing products from domestic pharmaceutical manufacturers. This is a consensus reached before.
However, although these new drugs may be very effective in the laboratory, they still need to undergo clinical trials. If it is a general medical research and development process, it will not be possible to apply it to actual treatment in less than three to five years.
Because with the current level of drug research and development, it is almost impossible to develop drugs with small side effects and significant therapeutic effects from the beginning. Instead, they must be continuously improved in subsequent clinical trials until they are finally usable.
In this case, each clinical stage will take a very long time to deal with the complex side effects that have occurred, and then it will take time to improve. As time goes by, time will be delayed.
The drug research and development information provided by Zhao Yi to Chinese pharmaceutical companies does not have any side effects. Just like drinking water, too much water can cause poisoning. No matter how good the technology is, it cannot guarantee this.
However, the side effects are minimized and the possible side effects are also listed. The pathological research data on these side effects are priceless treasures for Chinese pharmaceutical companies.
Under foreseeable circumstances, the clinical stage can actually be skipped, because in addition to improving the medicine, the clinical stage is to discover the side effects of the medicine.
With the help of Zhao Yiji's medical side effects and pathological analysis and research, these can all be analyzed manually and have the effect of clinical trials.
However, even if Zhao Yi felt that there was nothing wrong with the side effect pathological analysis data and techniques he provided, he would not take it for granted. The risk was too great. If an accident occurred, he could not afford the consequences.
Therefore, every pharmaceutical research and development process that should be followed must not be omitted, and it is impossible to skip the clinical stage. This is not only prudent in research and development work, but also gives less excuses to relevant departments.
However, because the credibility and validity of these analyzes are particularly high, they are more targeted during the clinical trial phase and have certain plans for possible consequences.
Therefore, in the clinical trial phase, the number of experimental subjects can be increased and larger experimental samples can be obtained faster, which speeds up the clinical trial phase and shortens the entire drug development cycle.
According to normal medical clinical trial procedures, the first phase of clinical trials selects very small experimental subjects because medical researchers cannot predict the side effects of this drug.
Therefore, to be cautious, we must conduct experiments on a small scale and obtain some research samples. If there are no problems at this stage, we can enter the second stage of clinical trials and expand the number of experimental subjects.
Of course, if a problem is discovered, the first phase of the clinical trial will be stopped, the side effects that have occurred will be analyzed, and the drug will be improved.
Normal pharmaceutical research and development is stuck in this process for too long, which is why clinical trials often take more than ten years, or even decades.
Of course, extending the clinical time period is not necessarily entirely for this reason. It may also be to study whether the drug has side effects over a longer period of time.
Some side effects are invisible in the short term, and it may take more than ten years, or even decades, for obvious side effects to appear.
This kind of clinical trial can be carried out slowly if it is a disease for which drugs are not urgently needed, but for some serious diseases, there is not much time to waste, and this kind of research is meaningless.
For example, if a tumor has entered the mid-to-late stage and the patient has only a few days to live, he does not care about the side effects in the next few decades. Living in the present is the most important thing. The extra year he can live is only one year, and he has no choice.
The main research and development direction of Chinese pharmaceutical companies is specific drugs for this major disease. As for other conventional diseases, if there are no specific drugs, some medical methods can still be used to cure or delay the time.
However, this may bring greater costs to Chinese medical companies, because chronic diseases or diseases that require long-term maintenance are very costly.
If there is no relationship between Chinese medical companies and Chinese pharmaceutical companies, there is no need to care whether the cost expenses of Chinese medical companies are large. Anyway, there are many Chinese pharmaceutical companies that should make money.
But after all, they are a boss, and the boss is also a medical contractor, so they cannot think like this. What can be solved needs to be solved as soon as possible to help medical companies achieve the purpose of reducing medical costs.
Therefore, over the past year, Chinese pharmaceutical companies have been recruiting pharmaceutical R&D talents from all over the world. Even domestic graduate students in pharmaceutical R&D-related majors have been recruited to serve as interns.
In addition, there are R&D personnel supported by domestic pharmaceutical companies. Now it does not matter what the level of these personnel is, as long as they can skillfully operate biochemical experiments.
Because of the detailed research and development process, detailed information is already available. As long as you follow the diagram, you will definitely be able to research something. This is why pharmaceutical companies dare to start the research and development of so many drugs at the same time.
Because this work does not require a high degree of innovation ability, it only needs to be done step by step and according to the steps given in the information. It is basically a physical job and does not require a lot of mental work.
Of course, these drug information are very valuable. It can be said that if they are leaked before applying for a patent, it will cause huge losses to Chinese pharmaceutical companies.
Therefore, this research and development stage is completely closed. In the experimental base, they will be provided with almost all living facilities, and the conditions are much better than the units where they originally stayed.
Not only that, the salary offered to them by the Chinese pharmaceutical company is more than five times higher than that of their previous unit. The backbone of the business is even as high as 10 times or more than the original salary.
With such a high remuneration, being detained at the base for three to five years, let alone one year, is no problem for most people. After all, they only need to work for one or two years to earn retirement money for the rest of their lives. .
Of course, this is a research and development institution after all, not a prison, so he still allows relatives of these researchers, especially couples, to visit him. The research base will provide them with a special place and all fees are free.
However, before leaving the base, you need to go through a full-body inspection. It is very strict. Not even a piece of paper, not even a single bacteria, can pass the inspection. And after you go out, you will be reunited in a designated place, and you are not allowed to run around.
This process needs to continue until the new drug patent is obtained, and a strict confidentiality agreement must be signed. No internal research status of the experimental base can be said to the outside world.
This is why Zhao Yi judged that most of the drugs currently developed by Chinese pharmaceutical companies should also enter the clinical trial stage.
In less than half a year, these drugs need to undergo intensive clinical trials. No matter how confident you are in the medical research and development data you provide, it is impossible to save this time. This has already compressed the clinical stage to the extreme.
In addition to drug research and development, another important task for Chinese pharmaceutical companies is the construction of drug production plants. Because to meet the medical needs of China's one billion population, their number of production plants is very large.
Calculating one production factory for one drug, hundreds of drugs require the construction of hundreds of production factories. However, the actual situation is that one drug often requires several factories to produce it.
Because the production of medicines is not just a filling plant or a patent medicine production plant, but requires many pharmaceutical raw material production plants, so the pressure on Chinese pharmaceutical companies in this regard is not small.
If it is chemical raw materials, it is better. For many raw materials, you can ask Pusi Chemical Company for help. Pusi Chemical Company is a veritable chemical giant domestically and even internationally, producing almost all categories of chemical products.
Therefore, if you want to expand the production of chemical raw materials, you only need to build more factories and purchase more production equipment to achieve the purpose of rapidly expanding production. As long as you have money, there are basically no bottlenecks.
But not all raw materials are chemical raw materials. A considerable number of medicines use herbal raw materials, which are special extracts extracted from plants. Moreover, they are not just one kind of plant, and there are many types of plants involved.
If you want to expand the production of such drugs, you need to plant related plants on a large scale. The pharmaceutical company knew that its energy was limited. From the beginning, it entrusted Tianji Agriculture and Animal Husbandry Company with full authority to take charge of this aspect.
Because Tianji Agriculture and Animal Husbandry Company not only has a high technical level in plant cultivation, but they also have enough money and resources to expand the cultivation scale of medicinal plants.
As for the production equipment of pharmaceuticals, all are entrusted to precision instrument companies to be responsible for R&D and production. Because a high level of automation is required, currently only precision instrument companies in China can complete this work.
It seems that there is no problem. All you need to do is complete your respective tasks step by step. In fact, this is indeed the case. If the progress in all aspects can be kept up, the set goals can be completed by then.
But this is only an ideal situation, so Zhao Yi needs to understand the completion status of these companies' tasks now, and also to supervise them, hoping that they will not delay the progress for no reason.
So Zhao Yi held a pharmaceutical production coordination meeting in Kyoto. The participating companies included China Pharmaceutical Company, Tianji Agriculture and Animal Husbandry Company, Tiangong Precision Instrument Company, and Tianshu Machinery Company.
As for the third-party construction companies that built the factories, Zhao Yi was not invited to participate in this coordination meeting. The specific urging work was completed by the China Pharmaceutical Company.
At the meeting, Zhao Yi first listened to the work progress of these companies, understood where their difficulties were, and then gave relevant solutions.
This meeting is not only an internal coordination meeting, but also a problem-solving meeting. Fortunately, Zhao Yi needs technology and capital. The problems that arise in the meeting are not problems at all when it comes to him, and they are all solved. .
At the end of the meeting, the relevant persons in charge of each company promised to complete the tasks according to the plan, and they were about to issue a military order.
If there are no problems in all aspects, the person in charge of the Chinese pharmaceutical company is also confident that the goal of large-scale production will be achieved before the end of the year, which can fully meet the medical needs of 1 billion people in the country.
After the meeting, Zhao Yi left the person in charge of the Chinese pharmaceutical company alone to understand the progress of their drug research, although Zhao Yi was very confident that he could complete the research and development of relevant pharmaceutical products as planned.
But after all, he is not doing it himself. Whether others can do what he expected is actually unknown, so he must understand the current situation in this regard, and it is also a kind of supervision for Chinese pharmaceutical companies.
Fortunately, China Pharmaceutical Company did not disappoint Zhao Yi. The current research and development progress of medicines and medical devices are all in accordance with the plan. Although there were occasional accidents, they were resolved by them.
There is no problem with technology, but the main problem is the shortage of manpower. In order to achieve the planned goals, in addition to the original recruitment channels, Chinese pharmaceutical companies have also begun to poach or borrow people from national units.
The government also knows the research and development pressure that Chinese pharmaceutical companies are facing now. Although it is a private enterprise, it bears the heavy burden of the country's future medical welfare and must be fully supported.
With permission from the government, coupled with the high salaries and various benefits offered by Chinese pharmaceutical companies, all domestic chemical and biological researchers have been summoned.
In fact, this cooperation does not benefit Chinese pharmaceutical companies unilaterally. In the past, domestic pharmaceutical research and development levels were actually not very good. Although there were occasional outstanding results, overall, they were still far behind Western developed countries.
However, after cooperating with Chinese pharmaceutical companies, the situation may be greatly improved, because Chinese pharmaceutical companies are at the top level in the world in terms of advanced equipment and drug research and development ideas.
Although after the cooperation ends, they will not be able to copy related drugs or use related patents, but the concepts and ideas are real, which will be of great reference value for their future biochemical research.
At the same time, they did not know the level of experimental equipment of Precision Instrument Company before, because these products of Precision Instrument Company were basically provided by related companies and units.
In fact, not many outsiders know about the situation, and there are not that many academic conferences now. Even if there are, because Precision Instrument Company is a private enterprise and is famous for being unpretentious, good things are always reserved for itself and its brother companies.
The instruments and equipment sold for takeout are all at least one level up, so although everyone knows that Zhao Yi owns a large company that specializes in the development and production of precision instruments and equipment, no one has a specific idea of what the technical level is.
In addition, some research institutions have not yet turned a corner, and they still feel that foreign instruments and equipment are definitely more advanced than domestic ones, so they would rather trust foreign products for some advanced experimental equipment.
The emergence of this situation is because our country has developed too fast in recent years, and Zhao Yi's companies have developed even faster. Many people's concepts have not caught up, or they have not had enough time to react.
Moreover, some domestic national scientific research institutes have not stimulated independent initiative. They still carry out relevant research according to the tasks assigned by the superiors, and pay little attention to changes in the market.
This cooperative research and development must have a great impact on them. It is not only a baptism in research and development thinking, but also a new understanding of modern research equipment.
Nowadays, if we want to produce good things, how can we do without high-tech and highly sensitive experimental equipment? Without these things, a lot of research and development can only remain on paper.
Therefore, this cooperation is a win-win cooperation for both parties. The plans of Chinese pharmaceutical companies can be completed as scheduled, and the scientific research capabilities of major domestic chemical and biological institutes will also be greatly improved in the future.
After handling the matter of China Medical Company, Zhao Yi summoned the heads of China Medical Company to come over and listen to them about the implementation progress of China Medical Company's related projects.
China Medical Corporation has three main tasks. The first is to build enough hospitals and health clinics to meet the diagnostic needs of people across the country for various diseases. This is actually left to third-party builders.
Their main task is to supervise and determine the construction progress of various construction contractors. Although a lot of manpower is needed, people in this area are actually very easy to find and do not have much technical content.
The second aspect is the procurement of medical equipment, as well as the selection and deployment of medical personnel. To say whether there are many medical personnel in the country, it is not actually too many. To say there are few, there is definitely a lot.
But the ingredients here are very complicated. In addition to doctors from regular schools, there are also many quacks and barefoot doctors. These people may not have comprehensive theoretical knowledge, but their practical skills are not weak at all.
Now is just the employment period. Chinese medical companies actually cherish these medical personnel who were not recognized in their previous lives. However, they do have their shortcomings, and their professional abilities need to be fully tested.
Then it involves the third task of the medical company, which is to conduct comprehensive and detailed training for medical personnel across the country, which includes not only these quacks and barefoot doctors, but also medical personnel from regular hospitals.
The content of the training is the medical diagnosis manual for various diseases compiled by Zhao Yi for a Chinese medical company. Although it is not a manual, the content involved is very huge. It can be said to be a medical encyclopedia.
If there is a unified training, it is estimated that no medical staff can say that they can master it comprehensively, so it is better to train according to their professional direction, which is more targeted.
As for those quacks and barefoot doctors, they also need to be trained in relevant medical and medical theories. Only when they have a solid grasp of this aspect can they start professional training in medical direction.
If manpower is used to carry out the work in this area, not to mention whether everyone can reach the level of a trainer, even if the manpower is not enough, and individual differences are huge, it is difficult to achieve the purpose of differentiated training if only through live video teaching.
So Zhao Yi planned to use compulsory education methods for training from the beginning. Yes, he used smart medical trainers to train medical personnel across the country.
In order to take care of the differences, it is not like compulsory education, where students all sit in the classroom for unified training. Instead, they are equipped with personal handheld computers developed by Polaris Company, that is, tablet computers. There is no problem with using personal PCs.
In this way, smart medical trainers can customize training courses that suit each individual according to their differences, and can also monitor their learning status in real time and rate their learning status.
At the end of a learning period, they will be given a comprehensive score. This score will affect their salary and rank benefits, so it is very important to them and they must go all out.
Of course, this medical reform is an opportunity for many medical practitioners to redefine their status.
As long as you perform well in this learning process, you may be an intern before, and now you may directly sit in the position of chief doctor.
Of course, if you want to achieve this, you must not only pass the assessment of smart medical trainers, which is purely knowledge-based learning after all, but in the medical field, it pays more attention to operational and practical abilities.
Therefore, they only get a replacement quota. If they want to get real treatment, they need to obtain higher evaluation through relevant practical operation evaluation in their actual work in the future.
"Unity of knowledge and action" is particularly important in the medical field. Only saying that it is of no use at all on certain issues, such as surgery, which requires very high practical ability of doctors.
From this meeting, Zhao Yi learned that all projects of China Medical Company are proceeding according to plan, and some projects are even slightly ahead of schedule, that is, the construction of related hospital clinics.
It turns out that the construction of local hospitals and health clinics has won strong support from local people. Many of them even helped the construction companies free of charge, hoping to build them as soon as possible so that they could enjoy free medical services nearby.
Especially in remote and rural areas, their desire for free medical care is very strong.
In many areas, there is no formal health clinic. There are only small clinics run by barefoot doctors. Serious diseases are basically out of reach.
If you want to go to a big hospital, the journey is too far, and the transportation is inconvenient, so many people just drag it and lose it.
Hearing what Zheng Xiyao, the president of China Medical Company, said, Zhao Dun was silent for a moment. He felt his eyes were a little sore. At the same time, he felt that it was worthwhile and proud for him to bear so much pressure and take on such a heavy burden. (End of chapter)